A-A-0053361(DM)
13 February 1988
INTERIM COMMERCIAL ITEM DESCRIPTION
THEOPHYLLINE CAPSULES, MODIFIED
The General Services Administration has authorized the use of this Interim Commercial Item Description which was developed by the Defense Personnel Support Center, Directorate of Medical Materiel, DPSC-RST, 2800 South 20th Street, Philadelphia, PA 19101, based upon currently available technical information.
Salient characteristics:
Shall be sustained-release Theophylline Capsules.
For Strength 1, shall contain 50 mg of anhydrous Theophylline per capsule, within the applicable assay limits.
For Strength 2, shall contain 60 mg of anhydrous Theophylline per capsule, within the applicable assay limits.
For Strength 3, shall contain 100 mg of anhydroua Theophylline per capsule, within the applicable assay limits.
For Strength 4, shall contain 125 mg of anhydrous Theophylline per capsule, within the applicable assay limits.
For Strength 5, shall contain 200 mg of anhydroua Theophylline per capsule, within the applicable aasay limits.
For Strength 6, shall contain 250 mg of anhydrous Theophylline per capsule, within the applicable assay limits.
For Strength 7, shall contain 300 mg of anhydrous Theophylline per capsule, within the applicable aasay limits.
The sustained-releaae capaule must be considered by the FDA to be therapeutically equivalent with Theophylline Capsules by Rorer Pharmaceutical Corporation, Subsidiary of Rorer Group, at the same dosage and adminiatrative schedule.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business